Advisory
Strategy that survives contact with the economics.
Most molecular-energy strategies fail in the same place: they are built on an assumed cost curve and an assumed buyer. MolecularX builds strategy from the other direction — from the technologies that exist, the projects that are moving, the buyers who are actually contracting, and the delivered cost you can defend to an investment committee.
internal Delivered by MolecularX.
The problem
Hydrogen and its derivatives have generated more strategy documents than projects. The documents are usually not wrong about the direction; they are wrong about the sequence, the cost and the customer. A strategy that assumes a price point nobody has yet paid, or a buyer segment nobody has yet contracted, produces a plan that stalls at the first funding gate.
What you end up with
A strategy you can take to a board or an investment committee, with the economics attached and the first commercial moves already identified.
What this includes
- A defensible position: which molecules, which markets, which technologies, in what order
- The economics behind each option, with the assumptions visible and sensitivity-tested
- A ranked shortlist of moves, with what each requires and what each is worth
- The commercial map — who the real buyers, suppliers and partners are for the chosen path
How we approach it
Start from the market, not the molecule
Who buys, at what price, under what contract, with what certification requirement. If that question has no answer, the strategy has no foundation.
Test the technology honestly
Maturity, efficiency, supply chain and delivered cost — including the cases where electrification beats a molecule. Technology-neutral is not a slogan here, it is the method.
Model the economics
Levelised cost, capital intensity, feedstock and electricity sensitivity, and what has to be true for the case to clear its hurdle rate.
Name the commercial route
A strategy that does not identify specific counterparties is an essay. We finish with who to talk to and why.
Questions
How is this different from a conventional consulting strategy engagement?
Two differences. First, the analysis is anchored in continuously monitored industry activity rather than in a one-off research sprint. Second, the engagement does not end at a document — MolecularX can carry the strategy into commercial introductions, because finding counterparties is part of what the business does.
Will you tell us not to pursue hydrogen?
If that is what the economics say, yes. Sometimes direct electrification is the better answer, and a strategy that cannot reach that conclusion is not worth commissioning. Technology neutrality is the point of the exercise.
Which molecules do you cover?
Hydrogen, ammonia, methanol, methane and biomethane, CO2, e-fuels and synthetic fuels, plus the carriers and conversion steps between them. Hydrogen is the entry point; the molecular-energy system is the scope.
Related
Market Analysis
Who is buying, who is selling, at what price, along which corridors — and where that leaves you.
Read more →Techno-Economic Analysis
Levelised cost modelling with the assumptions exposed and the sensitivities tested.
Read more →Technology Assessment
Independent, criteria-driven comparison of the technologies competing for your project.
Read more →Where are you starting from?
Tell us what you provide, what you need and where you operate. The first conversation is about whether we can actually help, which is a faster question than it sounds.